This guideline summary has been replaced by an updated version. Please update your bookmarks.
View the updated summary: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed. NGC:010890
View all updated summaries in the Guideline Archive.
About NGC Guideline Summaries
NGC's guidelines summaries contain information systematically derived from original guidelines.
New on NGC
New This Week
View more and sign up for our Newsletter